Rintatolimod
Rintatolimod is an oligonucleotide pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
COVID-19
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
23 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic fatigue syndrome | D015673 | EFO_0004540 | G93.31 | — | — | 1 | — | 1 | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | 2 | — | — | 2 | 6 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 3 | 1 | — | — | — | 3 |
| Colorectal neoplasms | D015179 | — | 2 | — | — | — | 2 | ||
| Covid-19 | D000086382 | U07.1 | 1 | 2 | — | — | — | 2 | |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | 2 | — | — | — | 2 |
| Hiv seropositivity | D006679 | — | 2 | — | — | — | 2 | ||
| Prostatic neoplasms | D011471 | C61 | — | 1 | — | — | — | 1 | |
| Adenocarcinoma | D000230 | — | 1 | — | — | — | 1 | ||
| Melanoma | D008545 | — | 1 | — | — | — | 1 | ||
| Carcinoma | D002277 | C80.0 | — | 1 | — | — | — | 1 |
Show 7 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Triple negative breast neoplasms | D064726 | 2 | — | — | — | — | 2 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | RINTATOLIMOD |
| INN | rintatolimod |
| Description | Rintatolimod, sold under the tradename Ampligen, is a medication intended for treatment of chronic fatigue syndrome (CFS). There is some evidence it may improve some CFS symptoms.
|
| Classification | Oligonucleotide |
| Drug class | immunomodulators: immunomodulators, toll-like receptor agonists |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 38640-92-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2107862 |
| ChEBI ID | — |
| PubChem CID | 135537060 |
| DrugBank | — |
| UNII ID | 94325AJ25N (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 213 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,610 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more